

Evolve BioSystems launches Evivo in Hong Kong, Singapore

21 May 2019 | News

The introduction of Evivo into these markets fulfills a major goal of the Bill & Melinda Gates Foundation and Horizons Ventures, the investment arm of the Li Ka Shing Foundation



Evolve BioSystems, makers of Evivo® baby probiotic, announced that its flagship consumer product Evivo is available in Hong Kong and Singapore. Evivo, an activated form of *B. infantis*, an essential beneficial bacterium for babies.

The introduction of Evivo into these markets fulfills a major goal of the Bill & Melinda Gates Foundation and Horizons Ventures, the investment arm of the Li Ka Shing Foundation. These two world-renowned public-health organizations led Evolve's most recent round of funding based on the company's science, which has shown that *B. infantis* reduces the abundance of pathogens, such as *Clostridium* and *E. coli*, that have been associated with autoimmune conditions common in developed nations, including asthma, allergies, colic, eczema and type-1 diabetes.

"The dramatic spike of autoimmune health challenges over the past several decades has spread in Asia, correlating with the rise of formula feeding, C-sections and antibiotic abuse. Evivo baby probiotic, the essential beneficial bacterium for babies, is critical in laying the foundation for a strong immune system," said Patrick Zhang at Horizons Ventures. "We were particularly eager to make Evivo available in Asia because we believe that *B. infantis* is critical for laying the foundation for a strong immune system."

Evivo is intended specifically for newborns, and provides a crucial strain of *Bifidobacterium* that was historically present in the infant gut, but has nearly been eliminated over the past century. When Evivo is consumed in combination with breast milk, the *B. infantis* crowds out pathogens.

"Although the modern medical interventions common in developed societies are often medically necessary, they have some major unintended consequences. The disrupted microbiomes among the infants of these populations is a notable example," said Tim Brown, CEO of Evolve BioSystems. "Today, the launch of Evivo in Singapore and Hong Kong markets marks the first step toward our larger goal of beneficially remodeling the microbiomes of Asian babies for strong and lifelong immune health."